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temperature 37.8 ºC. There were anemic conjuctiva, 
madarosis of his eyebrows, and also saddle nose. 
Another positive fi ndings includes evidence of 
arthritis on both knees, elbows, shoulders, ankles, 
wrists, and also proximal interphalangeals I-V of 
both hands. There were clawed hands, dropped 
feet, and enlargement of ulnar and posterior tibial 
nerves of both sides, maculopapular plaques 
with erythema at the back, hands, and legs, and 
also dry skin at both palms and soles. There 
were also pitting edema on both feet. Abdominal 
examination showed mild splenomegaly (S1). 
Due to the clinical manifestations (symmetrical 
polyarthritis, hand arthritis, and morning stiffness 
more than 6 month) the patient was suspected 
suffering from rheumatoid arthritis.
Figure 1  A. The patient with madarosis of eyebrows and 
saddle nose; B. Clawed hand (see ring fi nger and little 
fi nger); C. Arthritis at proximal interphalangeal joints; D. 
Arthritis of right knee.
Laboratory examinations revealed Hb 8.8 g/dL 
normochromic normocytic, leucocyte 4,100/uL, 
thrombocyte count 130,000/uL, ESR 60 mm/h, 
CRP 1.69 mg/dL, random blood sugar 115 mg/dL, 
BUN 51.9 mg/dL, serum creatinine 1.26 mg/dL, 
AST 29 IU/L, ALT 16 IU/L, ANA 7.7 U (negative), 
negative RA factor, and anti CCP 8 IU/ml. Chest 
X-Ray was normal. Anteroposterior hands x-ray 
revealed soft tissue swelling and juxtaarticular 
osteoporosis. Abdominal ultra sonogram showed 
splenomegaly.
Currently leprosy is now still a global threat in 
the world even after the introduction of multidrug 
therapy (MDT), including in Indonesia.1 World 
Health Organization (WHO) data revealed that 
in 2002 there were 597,000 cases worldwide and 
the prevalence is only less than 1 every 10,000 
populations.2 Nevertheless, the latest data showed 
that 83% of leprosy cases concentrated in only 6 
countries: Indonesia, India, Brazil, Madagascar, 
Myanmar, and Nepal.3
The most common manifestations of leprosy 
are cutaneous and neuritic manifestation. 
Rheumatologic manifestation is another common 
manifestation of leprosy.4-7  Prevalence of 
rheumatologic manifestation of leprosy is range 
from 1% to 77% of all leprosy patients.4-11 Study 
conducted by Mandal et al in India revealed that 
the prevalence of rheumatologic manifestation was 
5.9%, in Brazil,6 another study by Pereira revealed 
the prevalence of 9.1%.5 Hadi, in Indonesia, 
showed the prevalence of arthritic manifestation 
was 7.5%.8 Rheumatologic manifestations 
that can be found in leprosy are polyarthritis 
or oligoarthritis, soft tissue rheumatism, non-
infl ammatory arthritis, and also enthesitis.4-7 We 
report a patient presenting with polyarthritis as the 
primary manifestation of leprosy.
CASE REPORT
A 28 years old male patient came to our hospital 
with chief complaint of joints pain. Patient had 
suffered joints pain at both knees, shoulders, 
elbows, wrists, and fi ngers of both hands since 
8 months intermittently. Joints pain usually 
accompanied by swelling and morning stiffness 
last for about an hour. In the last 2 weeks priot 
to admission, joints pain was more severe so the 
patient had diffi culty to walk. The patient also had 
on and off low grade fever in the last 8 months. He 
used to take non steroid anti infl ammation drugs 
(NSAIDs) and the pain as well as infl ammation was 
relieved. He also had stiffness of his ring fi ngers 
and little fi ngers on both sides so it was diffi cult 
to move those fi ngers. His father and mother had 
history of leprosy and already completed the 
medications about 20 years ago. 
On admission, the patient was fully alert, 
blood pressure 110/70 mmHg, pulse rate 102 
times/minute, respiratory rate 18 times/minute, 
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Figure 2  Anteroposterior view of both hands x-ray revealed soft tissue 
swelling and juxtaarticular osteoporosis
Because of our highly suspicion of leprosy, we examined 
patient’s ear lobe plasma for the presence of acid-fast 
bacilli. It revealed positive result and confi rmed diagnosis 
of multibacillary (MB) type of leprosy with type 2 leprosy 
reaction and we took care the patient together with dermatology 
department.
The patient was diagnosed with MB type of leprosy with 
type 2 severe leprosy reaction with chronic polyarthritis 
manifestation and anemia of chronic disease. He was treated 
with PRC transfusion, sodium diclofenac 50 mg b.i.d., 
methylprednisolone 24 mg once daily (with tapering off 4 mg 
every 2 weeks), omeprazole 20 mg b.i.d., folic acid 500 mcg/
day, B1 100 mg bid, B6 200 mg b.i.d., and B12 200 mcg b.i.d. 
The patient was also treated with MDT consists of rifampicin 
600 mg monthly, clofazimin 300 mg monthly, and dapsone 
100 mg daily for 12 months. The joint pain and swelling 
subsided within 3 days after the treatment started, then he 
was discharged on the following day, with the instruction to 
continue the MDT treatment. The patient was followed up at 
outpatient department and showed remarkable improvement. 
There was no arthritis.
DISCUSSION
Leprosy is still a global health problem especially in Indonesia. 
World Health Organization classifi es leprosy as paucibacillary 
(PB) and multibacillary (MB). Paucibacillary leprosy has less 
than 5 anaesthetic plaques, only 1 nerve involvement, and 
negative acid fast bacilli, while MB leprosy has more than 
5 anaesthetic plaques, with more than 1 nerves involvement, 
and also positive acid fast bacilli. One of leprosy complication 
is leprosy reaction. The reaction can occur before, during, 
or after leprosy treatment. There are two types of leprosy 
reactions: type 1 and type 2. Pathogenesis of type 1 leprosy 
reaction involves the amelioration of cellular immunity in 
leprosy patient, while type 2 involves the amelioration of 
humoral immunity. Type 1 leprosy reaction is characterized 
by mild fever, worsen skin and neurologic manifestation with 
rare other organ involvement, and it can be happened both in 
PB and MB type. Type 2 leprosy reaction is characterized by 
fever, generalized weakness, worsen skin manifestation which 
is sometimes accompanied by erythema nodusum leprosum 
(ENL).  Common other organs involvement are joint, eye, 
testicle, renal, lymph node, and it can only  occur in MB type 
leprosy.2,3,12 Our patient’s diagnosis of MB leprosy was based 
on our fi ndings of long-term contact with leprosy patients (his 
parents), fever, madarosis, saddle nose, enlargement of more 
than 2 nerves (ulnar and posterior tibial), clawed hands, and 
dropped foot that was confi rmed by positive fi ndings of acid 
fast bacilli on ear lobe serum examination. Diagnosis of type 2 
leprosy reaction are also established by the presence of fever, 
weakness, arthritis (extradermal and neural manifestation) and 
the diagnosis of MB type leprosy.
Rheumatologic manifestation is the most prevalent 
manifestation of leprosy after dermatologic and neurologic 
manifestation.4-7,10-12 There were some cases reported leprosy 
without any dermatologic manifestation and preceded with 
pure rheumatologic or neuritic leprosy.9,13-18 Polyarthritis, 
oligoarthritis, soft tissue rheumatism, non-infl ammatory 
arthritis and enthesitis can be the manifestation of leprosy in 
earlier stage.4,6,7,10,11,19 The common mechanisms of leprosy 
arthritis is the presence of leprosy reaction in which intra-
articular immune-complex depositions and complement 
activations cause arthritis and also concomitant with activation 
of cellular immune response by recruitment of infl ammatory 
cells to the joints structure. Several studies also revealed that 
the most frequent leprosy rheumatologic manifestation is oligo-
/polyarthritis with remarkably resemblance with rheumatoid 
arthritis.5,9 Several researches have been conducted to know 
the association between leprosy and rheumatoid arthritis. 
It is likely that the resemblance between leprosy arthritis 
manifestation especially in leprosy reaction and rheumatoid 
arthritis is caused by the similarity in their pathogenesis, 
which is immune-complex deposition and complement 
activation due to the activation of humoral immune response 
and also activation T-cell (cellular immune response) leading 
to infl ammation process in the joints.20,21
The goal of leprosy reaction treatment is to suppress immune 
reaction that happened so we can prevent complications and 
disability and we still continue the leprosy medication.1 The 
MDT regiments recommended by WHO can be seen on table 
1.
Table 1  WHO-recommended multidrug therapy regiments for leprosy2,3,12
Type of 
leprosy
Drug treatment Duration of 
treatment 
(months)
Monthly 
supervised
Daily, self-
administered
Paucibacillary Rifampicin 600 
mg
Dapsone 100 mg 6
Multibacillary Rifampicin 600 
mg, Clofazimine 
300 mg
Clofazimine 50 
mg, Dapsone 
100 mg
12
Leprosy reaction can be treated with steroids, prednisone 
or prednisolone 40 mg per day with tapering off 5 mg every 
2-4 weeks after demonstration of improvement.2,3,12 One 
randomized controlled trial study concluded that prednisolone 
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30 mg tapered slowly to zero over 20 weeks was superior to 
prednisolone 60 mg tapered over 12 weeks.12 Thalidomide 
300–400 mg daily has a dramatic effect in controlling ENL 
and preventing recurrences. Its use is limited because of 
teratogenicity (phocomelia) and possible neurotoxicity 
(although this does not appear to be a problem in leprosy 
patients).3,12 Clofazimine and pentoxifylline have both been 
used in ENL, but they are less effective than prednisolone 
or thalidomide.12 Colchicine and chloroquine have also 
been used with limited effect.12 Management of arthritis 
includes  giving of NSAIDs to decrease the infl ammation 
and pain immediately, but the main principle is to overcome 
the underlying process which is leprosy reaction by giving 
MDT and steroids.2,3,12 Although clinically the patient showed 
the manifestation of rheumatoid arthritis, the serology was 
negative. After treatment with NSAIDs (sodium diclofenac), 
metylprednisolone, and MDT for leprosy, the arthritis subsided 
within 3 days and it remained as such for more than a year of 
follow ups. Based on the result, we concluded that the chronic 
symmetrical polyarthritis (mimicking rheumatoid arthritis) in 
the patient was related to leprosy.
SUMMARY
We have reported a 28 years old male patient with leprosy 
with main manifestation of polyarthritis due to type 2 leprosy 
reaction. After establishing the diagnosis, with proper 
treatment consists of steroids, NSAIDs, and MDT according 
to WHO recommendation, the arthritis manifestation and 
leprosy reaction was subsided.
REFERENCES
 1. Handayani S. Leprosy elimination in year 2000. CDK 1997;117:10-2.
 2. Britton WJ, Lockwood DNJ. Leprosy. The Lancet 2004;363:1209-19.
 3. Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian 
physicians. CMAJ 2004;170(1):71-8.
 4. Gibson T, Ahsan Q, Hussein K. Arthritis of leprosy. British J Rheumatol 
1994;33:963-6.
 5. Perreira HLA, Ribeiro SLE, Pennini SN, Sato EI. Leprosy-related joint 
involvement. Clin Rheumatol 2009;28:79-84.
 6. Mandal SK, Sarkar RN, Sarkar P, Datta S, Bandyopadhyay R, 
Bandyopadhyay D, et al. Rheumatological manifestations of leprosy. J 
Indian Med Assoc 2008;106:165-6.
 7. Vengadakrishnan K, Saraswat PK, Mathur PC. A study of 
rheumatological manifestations of leprosy. Indian J Dermatol Venereol 
Leprol 2004;70(2):76-8.
 8. Hadi S. Arthritis of leprosy: clinical, laboratory, and radiological 
manifestations. Journal MMI 2007;42(1):46.
 9. Sheetal S, Arvind C. Lest we forget Hansen’s disease (leprosy): an 
unusual presentation with an acute onset of infl ammatory polyarthritis 
and the rheumatology experience. Int J Rheum Dis 2009;12:64-9.
 10. Atkin SL, El-Ghobarey A, Kamel M, Owen JP, Dick WC. Clinical and 
laboratory studies of arthritis in leprosy. BMJ 1989;298:1423-5.
 11. Atkin SL, El-Ghobarey A, Kamel M, Owen JP, Dick WC. Clinical and 
laboratory studies in patients with leprosy and enthesitis. Ann Rheum 
Dis 1990;49:715-7.
 12. Walker SL, Lockwood DNJ. The clinical and immunological features of 
leprosy. Brit Medical Bull 2006;77-78:103-21.
 13. Haroon N, Agarwal V, Aggarwal A, Kumari N, Krishnani N, Misra 
R. Arthritis as presenting manifestation of pure neuritic leprosy- a 
rheumatologist’s dilemma. Rheumatology 2007;46:653-6.
 14. Agarwal V, Singh R, Chauhan S, Sachdev A, Mohan H. Pitting edema 
with arthritis as the presenting manifestation of type I lepra reaction. J 
Indian Rheumatol Assoc 2004;12:123-6.
 15. Agarwal V, Wakhlu A, Aggarwal A, Misra R. Tenosynovitis as the 
presenting manifestation of leprosy. J Indian Rheumatol Assoc 
2002;10:69-70.
 16. Al-Raquum HA, Uppal SS, El Abdalghani RAR, Lasheen I. First report 
of leprosy presenting as acute polyarthritis in the setting of type I 
downgrading lepra reaction. Clin Rheumatol 2005;25:101-5.
 17. Helling CA, Locursio A, Manzur ME, de Fonseca MLS. Remitting 
seronegative symmetrical synovitis with pitting edema in leprosy. Clin 
Rheumatol 2005;25:95-7.
 18. Karat ABA, Karat S, Job CK, Furness MA. Acute exudative arthritis 
in leprosy- rheumatoid-arthritis-like syndrome in association with 
erythema nodusum leprosum. BMJ 1967;3:770-2.
 19. Atkin SL, Welbury RR, Stanfi eld E, Beavis D, Iwais B, Dick WC. 
Clinical and laboratory studies of infl ammatory polyarthritis in patients 
with leprosy in Papua New Guinea. Ann Rheum Dis 1987;46:688-90.
 20. Panayi GS. Does rheumatoid arthritis have a clinicopathological 
spectrum similar to that of leprosy? Ann Rheum Dis 1982;41:102-3.
 21. Wager O. Immunological aspects of leprosy with special reference to 
autoimmune diseases. Bull WHO 1969;41:793-804.
